凯因科技：撤回培集成干扰素α-2注射液（新增乙肝适应症）药品注册申请

Core Viewpoint - The company, Kaiyin Technology, has received approval from the National Medical Products Administration to withdraw its drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) [1] Group 1: Company Actions - The company has decided to withdraw the drug registration application based on a principle of prudence [1] - As a result of this decision, the company will fully recognize an asset impairment provision related to the development expenses of the Pegylated Interferon α-2 Injection project [1] Group 2: Financial Impact - The recognition of the asset impairment provision will lead to a reduction in the company's total profit for the year 2025 by 111 million yuan [1]